Christopher M. McBride

584 total citations
15 papers, 295 citations indexed

About

Christopher M. McBride is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Christopher M. McBride has authored 15 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Christopher M. McBride's work include Chemical Synthesis and Analysis (5 papers), Melanoma and MAPK Pathways (4 papers) and Synthesis and biological activity (3 papers). Christopher M. McBride is often cited by papers focused on Chemical Synthesis and Analysis (5 papers), Melanoma and MAPK Pathways (4 papers) and Synthesis and biological activity (3 papers). Christopher M. McBride collaborates with scholars based in United States, Switzerland and Japan. Christopher M. McBride's co-authors include Cynthia M. Shafer, Paul A. Renhowe, Sylvia Ma, Johanna M. Jansen, Barry H. Levine, Sharadha Subramanian, Payman Amiri, Savithri Ramurthy, Abran Costales and Darrin D. Stuart and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Tetrahedron Letters.

In The Last Decade

Christopher M. McBride

15 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher M. McBride United States 12 175 162 72 48 22 15 295
Prashi Jain United States 13 180 1.0× 129 0.8× 49 0.7× 26 0.5× 16 0.7× 22 342
Mark A. Bobko United States 11 194 1.1× 197 1.2× 45 0.6× 26 0.5× 17 0.8× 16 344
Jesús Vázquez Spain 10 265 1.5× 100 0.6× 65 0.9× 54 1.1× 29 1.3× 12 368
Yoshiaki Washio United Kingdom 8 192 1.1× 215 1.3× 50 0.7× 51 1.1× 17 0.8× 11 373
Dominik Hauser Germany 10 188 1.1× 232 1.4× 28 0.4× 49 1.0× 16 0.7× 11 347
Majid Ghasemian Iran 9 168 1.0× 146 0.9× 42 0.6× 29 0.6× 9 0.4× 26 322
Taijin Wang China 10 264 1.5× 201 1.2× 124 1.7× 45 0.9× 26 1.2× 25 447
Pascal Savy United Kingdom 8 141 0.8× 70 0.4× 42 0.6× 28 0.6× 15 0.7× 11 211
Nemanja Djoković Serbia 10 190 1.1× 88 0.5× 41 0.6× 67 1.4× 15 0.7× 17 294
Sudhakar Jakkaraj United States 7 208 1.2× 77 0.5× 100 1.4× 77 1.6× 22 1.0× 13 396

Countries citing papers authored by Christopher M. McBride

Since Specialization
Citations

This map shows the geographic impact of Christopher M. McBride's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher M. McBride with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher M. McBride more than expected).

Fields of papers citing papers by Christopher M. McBride

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher M. McBride. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher M. McBride. The network helps show where Christopher M. McBride may publish in the future.

Co-authorship network of co-authors of Christopher M. McBride

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher M. McBride. A scholar is included among the top collaborators of Christopher M. McBride based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher M. McBride. Christopher M. McBride is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ivetac, Anthony, Derek C. Cole, Douglas R. Dougan, et al.. (2020). Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp3 character and an exquisite selectivity profile. Bioorganic & Medicinal Chemistry Letters. 30(17). 127405–127405. 8 indexed citations
2.
Huang, Huey-Jing, Deepika Balakrishna, James Bilakovics, et al.. (2019). Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 371(2). 299–308. 6 indexed citations
3.
Cheruvallath, Zacharia S., Christopher M. McBride, Jun Feng, et al.. (2016). Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1. Bioorganic & Medicinal Chemistry Letters. 26(12). 2774–2778. 12 indexed citations
4.
Kiryanov, Andre A., Christopher M. McBride, Victoria A. Feher, et al.. (2016). Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(5). 1311–1315. 13 indexed citations
5.
McBride, Christopher M., Zacharia S. Cheruvallath, J. David Lawson, et al.. (2016). Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2. Bioorganic & Medicinal Chemistry Letters. 26(12). 2779–2783. 18 indexed citations
6.
Subramanian, Sharadha, Joelle Verhagen, Christopher M. McBride, et al.. (2015). Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Medicinal Chemistry Letters. 6(9). 961–965. 35 indexed citations
7.
Subramanian, Sharadha, Abran Costales, Barry H. Levine, et al.. (2014). Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors. ACS Medicinal Chemistry Letters. 5(9). 989–992. 11 indexed citations
8.
Lindvall, Mika, Christopher M. McBride, Thomas G. Gesner, et al.. (2011). 3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors. ACS Medicinal Chemistry Letters. 2(10). 720–723. 23 indexed citations
9.
Ramurthy, Savithri, Sharadha Subramanian, Mina Aikawa, et al.. (2008). Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors. Journal of Medicinal Chemistry. 51(22). 7049–7052. 72 indexed citations
10.
McBride, Christopher M., Paul A. Renhowe, Thomas G. Gesner, et al.. (2006). 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(14). 3789–3792. 16 indexed citations
11.
McBride, Christopher M., Paul A. Renhowe, Carla Heise, et al.. (2006). Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 16(13). 3595–3599. 40 indexed citations
12.
Frazier, Kelly, Christopher M. McBride, Sabina Pecchi, et al.. (2006). Design and structure–activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 16(8). 2247–2251. 11 indexed citations
13.
Frazier, Kelly, Timothy Machajewski, Christopher M. McBride, et al.. (2005). LHMDS mediated tandem acylation–cyclization of 2-aminobenzenecarbonitriles with 2-benzymidazol-2-yl acetates: a short and efficient route to the synthesis of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones. Tetrahedron Letters. 47(5). 657–660. 5 indexed citations
14.
McBride, Christopher M., Will Chrisman, Clifford E. Harris, & Bakthan Singaram. (1999). Efficient synthesis of substituted benzenes from 1,3-dienes or 1,4-cyclohexadienes with KMnO4 under mild conditions. Tetrahedron Letters. 40(1). 45–48. 12 indexed citations
15.
Ho, D H, et al.. (1975). PHARMACOLOGIC STUDIES OF CYCLOCYTIDINE AND ARABINOSYLCYTOSINE IN DOGS. Drug Metabolism and Disposition. 3(4). 309–313. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prashi Jain Breakdown of academic impact, for papers by Mark A. Bobko Breakdown of academic impact, for papers by Jesús Vázquez Breakdown of academic impact, for papers by Yoshiaki Washio Breakdown of academic impact, for papers by Dominik Hauser Breakdown of academic impact, for papers by Majid Ghasemian Breakdown of academic impact, for papers by Taijin Wang Breakdown of academic impact, for papers by Pascal Savy Breakdown of academic impact, for papers by Nemanja Djoković Breakdown of academic impact, for papers by Sudhakar Jakkaraj
Rankless by CCL
2026